Knockdown survivin expression reduces the efficacy of curcumin treatment in hepatocellular carcinoma cells

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3547-3555

  Hung, Chin Sheng ^a,b   Liu, Hui Hsiung ^c   Huang, Ming Te ^a,b,c   Cheng, Chao Wen ^a   Kuo, Li Jen ^a,b   Ho, Yuan Soon ^c   Wu, Chih Hsiung ^a,b,c   Chen, Chien Ming ^c   Wei, Po Li ^a,b   Chang, Yu Jia ^a,b,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; NITROBLUE TETRAZOLIUM; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOSENSOR; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE; CYTOTOXICITY; DRUG EFFICACY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; NICK END LABELING; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL SURVIVAL; CURCUMIN; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84868201760     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2393-4     Document Type: Article

References (33)

1. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215-9. (Pubitemid 38402113)
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17. (Pubitemid 37518510)
3. Thomas MB, Zhu AX. Hepatocellular carcinoma: The need for progress. J Clin Oncol. 2005;23:2892-9. (Pubitemid 46224106)
4. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614-6.
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997; 3:917-21. (Pubitemid 27353455)
6. Reed JC. The survivin saga goes in vivo. J Clin Invest. 2001; 108:965-9. (Pubitemid 32946070)
7. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-4. (Pubitemid 28563719)
8. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 2004;6:29-40. (Pubitemid 38391947)
9. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: Correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004;17:1378-85. (Pubitemid 39472993)
10. Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009;9:125.
11. Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, An J, et al. Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression. Ann Surg Oncol. 2010;17:3379-85.
12. Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: A meta-analysis of randomized trials. Anticancer Drugs. 2010;21:326-32.
13. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101:1535-42. (Pubitemid 36182531)
14. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004;23:4921-9.
15. Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, 2et al. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2007;363:738-44. (Pubitemid 47513692)
16. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: An ''old-age'' disease with an ''ageold'' solution. Cancer Lett. 2008;267:133-64.
17. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv Exp Med Biol. 2007;595: 127-48.
18. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? AAPS J. 2009;11:495-510.
19. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett. 2007;255:170-81. (Pubitemid 47268637)
20. Glienke W, Maute L, Wicht J, Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest. 2010;28:166-71.
21. Chang YJ, Tai CJ, Kuo LJ, Wei PL, Liang HH, Liu TZ, et al. Glucose-regulated protein 78 (GRP78) mediated the efficacy to curcumin treatment on hepatocellular carcinoma. Ann Surg Oncol. 2011;18:2395-403.
22. Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1703-9.
23. Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603-12.
24. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
25. Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci USA. 2008;105:3690-5. (Pubitemid 351723459)
26. Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Köhler K, et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol. 2008;10:211-9. (Pubitemid 351194051)
27. Monzo M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17:2100-4. (Pubitemid 29318841)
28. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas. 2001;23:251-8. (Pubitemid 32910973)
29. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071-4. (Pubitemid 28521163)
30. Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu HH, Chen HA, et al. Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells. Ann Surg Oncol. 2012;19:336-43.
31. Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, et al. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogenactivated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog. 2010;49:13-24.
32. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-6.
33. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer. 2008;44:2806-12.